Prescription Drug Monitoring Program (PDMP)

New York State

Information contained in this presentation is accurate as of September 2017
Meet the Speaker

• Anita Murray, R.Ph., Deputy Director
  Bureau of Narcotic Enforcement
  NYS Department of Health
• Administrator of the NYS Prescription Monitoring Program overseeing the implementation of new initiatives relating to PMP functionality and everyday operations.
• In this role since 2010.
What is a Prescription Drug Monitoring Program?

• A PDMP/PMP is a *statewide* electronic database which collects designated data on specified substances dispensed to or for patients. The PDMP is housed by a state regulatory, administrative or law enforcement agency. The housing agency disseminates information from the database to individuals who are authorized under state law to receive the information for purposes identified by state law.
New York State PMP Overview

• New York State Prescription Monitoring Program (PMP)
• Housed in the Bureau of Narcotic Enforcement (BNE) within the NYS Department of Health
• The Bureau has been collecting controlled substance data for decades. In June 2005 BNE started collecting all controlled substance data (Schedules II-V)
• The first version of the online PMP was launched in February 2010
• A newer, faster and more user friendly online version with more current prescription data was launched August 2013
New York State PMP Overview

How to Access the NYS PMP
Must have a NYS Health Commerce System Account

Health Commerce System Home Page—Click on the NYSPMP Icon
New York State PMP Overview

PMP Search Page
Requires Patient first and last name and DOB

Instructions
1. Enter the Required Patient Information in the fields indicated above.
2. Confirm your attestation and that the patient information is correct by clicking the "Yes" button.
3. On the following page, click on the "Continue" button.
   - If the indicated patient has filled one or more controlled substance prescriptions within the last twelve months, a report will be generated detailing those prescription(s).
   - If the indicated patient has not filled any controlled substance prescriptions within the last twelve months, a report will be generated indicating that fact.
New York State PMP Overview

• All controlled substance prescriptions in Schedules II-V must be reported by dispensers (including pharmacies, practitioners and veterinarians that dispense)

• Medical Marijuana dispensing data is also included in the New York State PMP

• Pharmacies and dispensing practitioners, that have previously dispensed a controlled substance, must file a zero report if they have not dispensed a controlled substance within the last 14 days

• In addition, manufacturers and distributors, licensed and doing business in NYS, must report their controlled substance sales and distribution to the Bureau of Narcotic Enforcement
Exceptions/Exclusions for Reporting

• Pharmacies and other dispensers that have received a waiver from the reporting requirements

• Pharmacies and other dispensers that have received a waiver from zero reporting. Zero reporting relates to those pharmacies and dispensers that may infrequently dispense controlled substances for which gaps may exist

• There are a number of exceptions. See 10 NYCRR 80.73(f)(2)
Data Exchange Time Period

- Pharmacies and dispensers are required to submit their data to the NYS Bureau of Narcotic Enforcement within 24 hour of dispensing (i.e., when the patient takes possession of the controlled substance).

- Required prescription data to be reported is detailed in regulation 10 NYCRR 80.73(f) and includes, but is not limited to, patient name, date of birth, address, drug identifier, strength, quantity, date prescription was issued, date dispensed, refill number, prescriber’s DEA number, payment method, pharmacy prescription number and identification number.
Approved Users

• Practitioners with the authority to prescribe and their designees are allowed direct access to the PMP (e.g., medical doctors, nurse practitioners, podiatrists, dentists). Veterinarians do not have access to the PMP.

• Pharmacists that have been presented a prescription for whom a controlled substance is written. They may designate another pharmacist or pharmacy intern to search the PMP.
Mandates

- Practitioners that write a prescription for a controlled substance in Schedules II-IV are mandated to consult the PMP within 24 hours prior to writing a prescription for a controlled substance.
- Veterinarians are exempt from the mandatory duty to consult.
- Practitioners that have received a waiver from the mandatory duty to consult are exempted.
- Pharmacists are NOT required to consult the PMP, although many do so voluntarily.
Limitations of Matching Data

• PMPs, including NY’s, generally do not have a unique patient identifier

• Identification of patients and matching relies on a relatively sophisticated algorithm. NY has included nicknames in this algorithm to ensure the best match

• NY’s PMP is configured to allow practitioners to see the varying results that may appear on a single name search (i.e., patient name at a different address, slight variation in DOB, etc.)
## Limitations of Matching Data

### Confidential Drug Utilization Report

**Search Terms:** Jack Spratt, M, 01/01/970  
**Search Date:** 05/29/2013 14:52:20

The Drug Utilization Report below displays all of the controlled substance prescriptions, if any, that your patient has filled in the last six months. The information displayed on this report is compiled from pharmacy submissions to the Department, and accurately reflects the information as submitted by the pharmacies.

This report was requested by Kevin D. Johnson

**Data Detail Level:** Printer-Friendly | Extended

### My Prescriptions

<table>
<thead>
<tr>
<th>Rx Written</th>
<th>Rx Dispensed</th>
<th>Drug</th>
<th>Strength</th>
<th>Quantity</th>
<th>Days Supply</th>
<th>Prescriber Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/29/2012</td>
<td>11/30/2012</td>
<td>Temazepam</td>
<td>15mg</td>
<td>30</td>
<td>30</td>
<td>Prescriber #10027096</td>
</tr>
<tr>
<td>08/23/2012</td>
<td>08/29/2012</td>
<td>Temazepam</td>
<td>15mg</td>
<td>30</td>
<td>30</td>
<td>Prescriber #10027096</td>
</tr>
<tr>
<td>07/24/2012</td>
<td>08/09/2012</td>
<td>Temazepam</td>
<td>15mg</td>
<td>30</td>
<td>30</td>
<td>Prescriber #10027096</td>
</tr>
</tbody>
</table>

### Others’ Prescriptions

<table>
<thead>
<tr>
<th>Rx Written</th>
<th>Rx Dispensed</th>
<th>Drug</th>
<th>Strength</th>
<th>Quantity</th>
<th>Days Supply</th>
<th>Prescriber Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/27/2012</td>
<td>06/30/2012</td>
<td>Temazepam</td>
<td>15mg</td>
<td>30</td>
<td>30</td>
<td>Prescriber #10027096</td>
</tr>
<tr>
<td>01/01/2012</td>
<td>01/01/2012</td>
<td>Hydrocodone</td>
<td>7.5/500mg</td>
<td>60</td>
<td>30</td>
<td>Prescriber #10290435</td>
</tr>
<tr>
<td>04/16/2012</td>
<td>09/10/2012</td>
<td>Hydrocodone</td>
<td>7.5/500mg</td>
<td>60</td>
<td>30</td>
<td>Prescriber #10290435</td>
</tr>
<tr>
<td>04/18/2012</td>
<td>08/12/2012</td>
<td>Hydrocodone</td>
<td>7.5/500mg</td>
<td>60</td>
<td>30</td>
<td>Prescriber #10290435</td>
</tr>
<tr>
<td>04/19/2012</td>
<td>07/12/2012</td>
<td>Hydrocodone</td>
<td>7.5/500mg</td>
<td>60</td>
<td>30</td>
<td>Prescriber #10290435</td>
</tr>
</tbody>
</table>

* * - Drugs marked with an asterisk are compound drugs. If the compound drug is made up of more than one controlled substance, then each controlled substance will be a separate row in the table.

To report a prescription discrepancy, please click here and enter the prescription information which may be a discrepancy.

To send questions or comments about this report to the Bureau of Narcotic Enforcement, please click here or call 1-800-811-7957 (Option 4).
Data Availability

• PMP data is accessed through a NYS Health Commerce System Application (HCS) for which an account is required. Access is granted to the PMP through a role based system (e.g., licensed practitioner with the authority to write a prescription, nurse, lay person).

• NYS Public Health Law is very clear on who shall have access to PMP data.

• PMP data is reviewed by BNE investigators for signs of potential abuse and diversion.
Other State Databases

- NY’s PMP is currently interoperable with 18 states and the District of Columbia
Analytics

• Currently, the NYS PMP provides information on all controlled substance prescriptions filled during the last year to a searcher

• Moving forward, Morphine Milligram Equivalents (MMEs) will be added to the report

• Patients and practitioners are not flagged
Trends and Use Patterns

- NYS PMP data is analyzed for trends, suspicious behavior and is shared as allowed under NYS Public Health Law

- Data is available on the following website and more information is expected to be continually added:

https://www.health.ny.gov/statistics/opioid/
Trends and Use Patterns

New York State Opioid analgesic prescription crude rate per 1,000 population

Source: NYS PMP data as of April 2017
Trends and Use Patterns

Opioid analgesics prescriptions age-adjusted rate per 1,000 residents, state of New York, 2016

- Age-adjusted to 2000 US population data
- 2016 NYS population data from The Nielsen Company (formerly Claritas)
- Prescriptions exclude buprenorphine for Substance Use Disorder (SUD), invalid zip codes, veterinary prescriptions and prescriptions for supply days greater than 90 days
- Counties are shaded based on quartile distribution

Source: NYS PMP, data as of April 2017
State PDMP Moving Forward

- Continually looking to make the PMP easier to use and efficient
- Add MMEs to the PMP patient report
- EHR integration pilot under a CDC grant
- Additional PMP data and a data dashboard available to the public including researchers
- For more information:

https://www.health.ny.gov/professionals/narcotic/prescription_monitoring/
QIN-QIO Involvement

• Why work with your QIN-QIO?
  o Access to data
  o Coordinated Efforts
    ▪ QPP Quality Measures & Improvement Activities
      ▪ Ex. Consultation of the PDMP (Activity ID: IA_PSPA_6)
  o Education and training
  o Process Improvement

• Additional QIN-QIO Information:

• IPRO is the QIO for NYS, for more information visit: http://atlanticquality.org/
  o IPRO Drug Safety Program Contact: Anne Myrka, anne.myrka@area-i.hcqis.org
Thank you for watching!

• For more information about New York’s Prescription Monitoring Program, please contact:
  o Anita Murray, R.Ph., Deputy Director
    - narcotic@health.ny.gov
    - 518-408-0248

https://www.health.ny.gov/professionals/narcotic/prescription_monitoring/